Approval for Galafold™ in patients with Fabry announced

Amicus Therapeutics, a biotechnology company at the forefront of rare and orphan diseases, today announced that the European Commission has granted full approval for the oral small molecule pharmacological chaperone Galafold™ (migalastat) as a first line therapy for long-term treatment